2 assets in Vaginal Melanoma

Therapeutic assets addressing Vaginal Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Vaginal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vaginal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)